Atrial fibrillation and hypertrophic cardiomyopathy: who to anticoagulate?

Antonio FronteraD G WilsonH SekhonE R DuncanG Thomas

Published in: Clinical research in cardiology : official journal of the German Cardiac Society (2015)

Hypertrophic cardiomyopathy (HCM) is one of the most common genetic cardiac conditions. Atrial fibrillation (AF) has been demonstrated to be the most frequent arrhythmia encountered in HCM patients. Research focusing on AF and embolic stroke in HCM patients has been sparse and the sample size of most studies is small. The prognostic significance of AF in HCM patients is still not well known. The aim of this article is to provide further understanding of the anti-coagulation requirement of HCM patients with AF.

Keyphrases

hypertrophic cardiomyopathy
atrial fibrillation
end stage renal disease
left ventricular
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
heart failure
peritoneal dialysis
catheter ablation
gene expression
oral anticoagulants
left atrial
dna methylation